Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) insider Cintia Piccina sold 11,890 shares of the business's stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $1.87, for a total transaction of $22,234.30. Following the completion of the transaction, the insider now directly owns 19,535 shares of the company's stock, valued at approximately $36,530.45. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Adaptimmune Therapeutics Trading Down 0.6 %
ADAP opened at $1.73 on Friday. Adaptimmune Therapeutics plc has a 12 month low of $1.01 and a 12 month high of $3.32. The business's 50-day moving average price is $1.71 and its 200-day moving average price is $1.74. The company has a market cap of $283.43 million, a P/E ratio of -1.59 and a beta of 2.23.
Get Adaptimmune Therapeutics alerts:Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last posted its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 112.16% and a negative net margin of 998.26%. The business had revenue of $7.01 million for the quarter, compared to analyst estimates of $4.40 million. Equities research analysts forecast that Adaptimmune Therapeutics plc will post -1.09 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on ADAP shares. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research report on Wednesday, October 12th. They issued a "hold" rating for the company. Wells Fargo & Company upped their price objective on Adaptimmune Therapeutics from $1.50 to $3.00 and gave the stock an "equal weight" rating in a report on Monday, November 14th. EF Hutton Acquisition Co. I started coverage on Adaptimmune Therapeutics in a report on Thursday, January 5th. They set a "buy" rating and a $10.00 price objective on the stock. Guggenheim raised Adaptimmune Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research note on Tuesday, January 3rd. Finally, Mizuho upgraded shares of Adaptimmune Therapeutics from a "neutral" rating to a "buy" rating and set a $9.00 price target on the stock in a research report on Wednesday, November 9th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, Adaptimmune Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $6.00.Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Hunter Associates Investment Management LLC boosted its position in Adaptimmune Therapeutics by 42.5% during the 2nd quarter. Hunter Associates Investment Management LLC now owns 28,500 shares of the biotechnology company's stock valued at $49,000 after buying an additional 8,500 shares during the period. Key Client Fiduciary Advisors LLC boosted its holdings in shares of Adaptimmune Therapeutics by 4.8% during the third quarter. Key Client Fiduciary Advisors LLC now owns 435,985 shares of the biotechnology company's stock worth $469,000 after purchasing an additional 19,819 shares during the period. Virtu Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 133.7% during the third quarter. Virtu Financial LLC now owns 40,503 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 23,175 shares during the period. State Street Corp grew its stake in shares of Adaptimmune Therapeutics by 4.2% in the first quarter. State Street Corp now owns 640,620 shares of the biotechnology company's stock worth $1,320,000 after purchasing an additional 25,627 shares during the last quarter. Finally, HBK Sorce Advisory LLC purchased a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $32,000.
Adaptimmune Therapeutics Company Profile
(Get Rating)
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Featured Articles
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.